Search

This article reports that the identification of poxvirus CD8+ T cell determinants enables the rational design and characterization of smallpox vaccines. The study was conducted by David C. Tscharke at the U.S. National Institutes of Health and collaborators in the U.S. and Australia. Tscharke and his coauthors published their study in the "Journal of Experimental Medicine." According to recent research from the United States and Australia, the large size of poxvirus genomes has stymied attempts to identify determinants recognized by CD8+ T cells and greatly impeded development of mouse smallpox vaccination models.

Discusses research being done on the rational design and characterization of smallpox vaccines through the identification of poxvirus CD8+ T cell determinants. Reference to a study by David C. Tscharke and coauthors published in the 2005 issue of the Journal of Experimental Medicine; Failure of modified vaccinia virus ankara to induce responses to tow of the defined determinants; Immunogenicity of several determinants in cowpox and ectromelia virus infections.

This article cites a study which says that poxvirus CD8+ T cell determinants aid smallpox vaccine design. The large size of poxvirus genomes has stymied attempts to identify determinants recognized by CD8+ T cells and greatly impeded development of mouse smallpox vaccination models. Here, researchers use a vaccinia virus (VACV) expression library containing each of the predicted 258 open reading frames to identify five peptide determinants that account for approximately half of the VACV-specific CD8+ T cell response in C57BL/6 mice. The research was conducted by David C. Tscharke. Tscharke and his coauthors published their study in the "Journal of Experimental Medicine."

The article cites a study which states that the identification of poxvirus CD8+ T cell determinants enables the rational design and characterization of smallpox vaccines. Researcher David C. Tscharke at the U.S. National Institutes of Health and collaborators in the U.S. and Australia used a vaccinia virus (VACV) expression library containing each of the predicted 258 open reading frames to identify five peptide determinants that account for approximately half of the VACV-specific CD8+ T cell response in C57BL/6 mice. Tscharke and his coauthors published their study in the "Journal of Experimental Medicine."

Reports on the study from the U.S. which found that the poxvirus p28 virulence factor is an E3 ubiquitin ligase. Disruption of the RING finger domain of p28 proteins; Catalysis of the formation of Lys-63-linked polyubiquitin chains; Potential of p28 to regulate the biological activity of the cognate viral and/or host cell targets.

Cites a study conducted by researchers in Germany, which reviews modified vaccinia virus Ankara as an antigen delivery system. Establishment of safety-tested modified vaccinia virus Ankara (MVA) as a potent vector system for the development of candidate recombinant vaccines; Consideration of MVA as a prime candidate vaccine for safer protection against orthopoxvirus infections; Possibility that vector development can challenge dilemmas in vaccinology or immunization against poxvirus biothreat.